» Articles » PMID: 28396938

Pravastatin Improves Postprandial Endothelial Dysfunction and Hemorheological Deterioration in Patients with Effort Angina Pectoris

Overview
Journal Heart Vessels
Date 2017 Apr 12
PMID 28396938
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Postprandial hypertriglyceridemia and hyperglycemia may promote endothelial and hemorheological dysfunction. The present study investigated the effects of pravastatin on endothelial function and hemorheology in patients with stable angina pectoris (AP) before and after eating a test meal. We recruited 26 patients with stable AP who had impaired glucose tolerance and mild dyslipidemia and six healthy men as controls to assess endothelial function and hemorheological behavior. In each group, we measured forearm blood flow (FBF) during post-ischemic reactive hyperemia and obtained blood samples before and 2 h after the test meal. Pravastatin 20 mg/day was then commenced in the 26 AP patients. The above tests were repeated after 2 days and 6 months. Maximum FBF during hyperemia in the baseline fasting phase was significantly lower in the AP patients than in the controls (p < 0.05). Fasting and postprandial FBF during reactive hyperemia time-dependently improved after pravastatin treatment (p < 0.05 vs. baseline data for each phase). Pravastatin treatment for 6 months, but not for 2 days, inhibited leukocyte activation and improved hemorheological parameters. In conclusion, pravastatin treatment for 6 months improved fasting and postprandial endothelial and hemorheological dysfunction in AP patients.

Citing Articles

Effect of Aggressive lipid-lowering treatment with Rosuvastatin on vascular endoTHelium function: evaluation of vascular endothelium function (EARTH study).

Takayama T, Hiro T, Yoda S, Fukamachi D, Haruta H, Kogo T Heart Vessels. 2017; 33(6):590-594.

PMID: 29209775 DOI: 10.1007/s00380-017-1094-0.


Effect of rosuvastatin on fasting and postprandial endothelial biomarker levels and microvascular reactivity in patients with type 2 diabetes and dyslipidemia: a preliminary report.

Kim K, Jung K, Yun H, Lee S, Oh T, Jang H Cardiovasc Diabetol. 2017; 16(1):146.

PMID: 29121934 PMC: 5679486. DOI: 10.1186/s12933-017-0629-0.


Ticagrelor mitigates ischaemia-reperfusion induced vascular endothelial dysfunction in healthy young males - a randomized, single-blinded study.

Weisshaar S, Litschauer B, Eipeldauer M, Hobl E, Wolzt M Br J Clin Pharmacol. 2017; 83(12):2651-2660.

PMID: 28715608 PMC: 5698593. DOI: 10.1111/bcp.13378.


Effects of pitavastatin on walking capacity and CD34/133 cell number in patients with peripheral artery disease.

Arao K, Yasu T, Endo Y, Funazaki T, Ota Y, Shimada K Heart Vessels. 2017; 32(10):1186-1194.

PMID: 28466409 PMC: 5614906. DOI: 10.1007/s00380-017-0988-1.

References
1.
Lowe G, Rumley A, Norrie J, Ford I, Shepherd J, Cobbe S . Blood rheology, cardiovascular risk factors, and cardiovascular disease: the West of Scotland Coronary Prevention Study. Thromb Haemost. 2000; 84(4):553-8. View

2.
Okumura K, Tsukamoto H, Tsuboi H, Hirayama H, Kamiya H, Watarai M . High HDL cholesterol level after treatment with pitavastatin is an important factor for regression in carotid intima-media thickness. Heart Vessels. 2014; 30(2):154-61. DOI: 10.1007/s00380-013-0466-3. View

3.
Higashi Y, Sasaki S, Sasaki N, Nakagawa K, Ueda T, Yoshimizu A . Daily aerobic exercise improves reactive hyperemia in patients with essential hypertension. Hypertension. 1999; 33(1 Pt 2):591-7. DOI: 10.1161/01.hyp.33.1.591. View

4.
Arao K, Yasu T, Umemoto T, Jinbo S, Ikeda N, Ueda S . Effects of pitavastatin on fasting and postprandial endothelial function and blood rheology in patients with stable coronary artery disease. Circ J. 2009; 73(8):1523-30. DOI: 10.1253/circj.cj-08-0917. View

5.
Perez-Sala D, Hernandez G, Diaz C, Lamas S . Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest. 1998; 101(12):2711-9. PMC: 508862. DOI: 10.1172/JCI1500. View